U.S. Markets open in 4 hrs 11 mins

Landos Biopharma, Inc. (LABP)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
3.1300-0.1200 (-3.69%)
At close: 04:00PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close3.2500
Bid0.0000 x 1100
Ask0.0000 x 1000
Day's Range3.0400 - 3.3500
52 Week Range2.7800 - 16.9890
Avg. Volume97,172
Market Cap131.234M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-0.9670
Earnings DateMar 29, 2022 - Apr 04, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est27.42
  • Simply Wall St.

    Here's Why We're Not At All Concerned With Landos Biopharma's (NASDAQ:LABP) Cash Burn Situation

    Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

  • GlobeNewswire

    Landos Biopharma Reports Third Quarter 2021 Financial Results and Provides Corporate Update

    Enhancing Focus on High-Impact Clinical-Stage Programs to Ensure Optimal Path to Commercialization Refining Ulcerative Colitis Clinical Development Plans for Omilancor to Generate Additional Phase 2b Data Prior to Initiating Pivotal Phase 3 Program Determining Optimal Enrollment for Phase 2 Clinical Study of Omilancor in Crohn’s Disease and Phase 1b Study of NX-13 in UC Initiated Dosing for LABP-104 in Healthy Volunteers in October 2021 with Results Expected in 1H 2022 Corporate Update Conferenc

  • GlobeNewswire

    Landos Biopharma to Host Corporate Update Call

    BLACKSBURG, Va., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Landos Biopharma Inc. (NASDAQ: LABP) today announced that it will report third quarter 2021 financial results and host a conference call to provide a corporate update on November 15, 2021. Following the release of the financial results, Landos will host a live webcast at 8:00 am ET. The webcast can be accessed through the Company’s investor relations website at, or by dialing 1-877-317-6789 (Toll Free) or 1-412-31